U.S. markets close in 1 hour 22 minutes
  • S&P 500

    4,169.16
    +44.50 (+1.08%)
     
  • Dow 30

    34,022.34
    +291.45 (+0.86%)
     
  • Nasdaq

    14,036.14
    +178.30 (+1.29%)
     
  • Russell 2000

    2,254.17
    +6.45 (+0.29%)
     
  • Crude Oil

    63.48
    +0.33 (+0.52%)
     
  • Gold

    1,767.40
    +31.10 (+1.79%)
     
  • Silver

    26.00
    +0.48 (+1.88%)
     
  • EUR/USD

    1.1980
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5340
    -0.1040 (-6.35%)
     
  • GBP/USD

    1.3791
    +0.0010 (+0.07%)
     
  • USD/JPY

    108.6360
    -0.2910 (-0.27%)
     
  • BTC-USD

    62,944.39
    -71.99 (-0.11%)
     
  • CMC Crypto 200

    1,382.63
    +1.68 (+0.12%)
     
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • Nikkei 225

    29,642.69
    +21.70 (+0.07%)
     

Syneos Health: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q4 results.

Quarterly Results

Earnings per share rose 7.77% year over year to $1.11, which beat the estimate of $1.10.

Revenue of $1,140,000,000 decreased by 6.02% year over year, which were in line with the estimate of $1,140,000,000.

Outlook

The upcoming fiscal year's EPS expected to be between $4.09 and $4.38.

The upcoming fiscal year's revenue expected to be between $5,125,000,000 and $5,325,000,000.

How To Listen To The Conference Call

Date: Feb 18, 2021

View more earnings on SYNH

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/h8kqo86z

Recent Stock Performance

Company's 52-week high was at $81.35

Company's 52-week low was at $30.02

Price action over last quarter: Up 47.21%

Company Overview

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.